These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 12176090

  • 1. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Dorne JL, Walton K, Slob W, Renwick AG.
    Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
    [Abstract] [Full Text] [Related]

  • 2. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors.
    Dorne JL, Walton K, Renwick AG.
    Food Chem Toxicol; 2003 Feb; 41(2):225-45. PubMed ID: 12480299
    [Abstract] [Full Text] [Related]

  • 3. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
    Malhotra B, Darsey E, Crownover P, Fang J, Glue P.
    Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
    [Abstract] [Full Text] [Related]

  • 4. Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs.
    Darney K, Lautz LS, Béchaux C, Wiecek W, Testai E, Amzal B, Dorne JLCM.
    Environ Int; 2021 Nov; 156():106760. PubMed ID: 34256299
    [Abstract] [Full Text] [Related]

  • 5. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF.
    Clin Pharmacokinet; 2009 Nov; 48(11):689-723. PubMed ID: 19817501
    [Abstract] [Full Text] [Related]

  • 6. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
    Brynne N, Böttiger Y, Hallén B, Bertilsson L.
    Br J Clin Pharmacol; 1999 Feb; 47(2):145-50. PubMed ID: 10190648
    [Abstract] [Full Text] [Related]

  • 7. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J.
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP.
    Clin Drug Investig; 2011 May; 31(3):155-67. PubMed ID: 21288052
    [Abstract] [Full Text] [Related]

  • 9. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
    Lindh JD, Annas A, Meurling L, Dahl ML, AL-Shurbaji A.
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
    [Abstract] [Full Text] [Related]

  • 10. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
    Fliegert F, Kurth B, Göhler K.
    Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences.
    Oishi M, Chiba K, Malhotra B, Suwa T.
    Drug Metab Pharmacokinet; 2011 Jun; 26(3):236-41. PubMed ID: 21273733
    [Abstract] [Full Text] [Related]

  • 12. Human variability in glucuronidation in relation to uncertainty factors for risk assessment.
    Dorne JL, Walton K, Renwick AG.
    Food Chem Toxicol; 2001 Dec; 39(12):1153-73. PubMed ID: 11696390
    [Abstract] [Full Text] [Related]

  • 13. Inter-individual variability of in vivo CYP2D6 activity in different genotypes.
    Chiba K, Kato M, Ito T, Suwa T, Sugiyama Y.
    Drug Metab Pharmacokinet; 2012 Dec; 27(4):405-13. PubMed ID: 22277677
    [Abstract] [Full Text] [Related]

  • 14. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
    Nichols AI, Lobello K, Guico-Pabia CJ, Paul J, Preskorn SH.
    J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
    [Abstract] [Full Text] [Related]

  • 15. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
    Brynne N, Forslund C, Hallén B, Gustafsson LL, Bertilsson L.
    Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic profile of fesoterodine.
    Malhotra B, Guan Z, Wood N, Gandelman K.
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):556-63. PubMed ID: 19000553
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.
    Lindskov Krog P, Osterberg O, Gundorf Drewes P, Rembratt Å, Schultz A, Timmer W.
    Eur J Drug Metab Pharmacokinet; 2013 Mar; 38(1):43-51. PubMed ID: 22948856
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.
    Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM.
    J Clin Psychopharmacol; 1998 Aug; 18(4):332-7. PubMed ID: 9690700
    [Abstract] [Full Text] [Related]

  • 20. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
    Tamminga WJ, Wemer J, Oosterhuis B, de Boer A, Vranckx S, Drenth BF, de Zeeuw RA, de Leij LF, Jonkman JH.
    Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.